Compare Glenmark Pharma with Cadila Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs CADILA HEALTHCARE - Comparison Results

GLENMARK PHARMA     Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA CADILA HEALTHCARE GLENMARK PHARMA/
CADILA HEALTHCARE
 
P/E (TTM) x 9.6 13.5 71.2% View Chart
P/BV x 1.4 2.2 61.9% View Chart
Dividend Yield % 0.7 1.6 47.1%  

Financials

 GLENMARK PHARMA   CADILA HEALTHCARE
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-19
CADILA HEALTHCARE
Mar-19
GLENMARK PHARMA/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs712432 164.6%   
Low Rs484306 157.8%   
Sales per share (Unadj.) Rs349.6128.6 271.9%  
Earnings per share (Unadj.) Rs32.818.5 176.8%  
Cash flow per share (Unadj.) Rs44.324.4 181.7%  
Dividends per share (Unadj.) Rs2.003.50 57.1%  
Dividend yield (eoy) %0.30.9 35.3%  
Book value per share (Unadj.) Rs198.6101.5 195.8%  
Shares outstanding (eoy) m282.171,023.74 27.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.72.9 59.5%   
Avg P/E ratio x18.219.9 91.5%  
P/CF ratio (eoy) x13.515.1 89.0%  
Price / Book Value ratio x3.03.6 82.6%  
Dividend payout %6.118.9 32.3%   
Avg Mkt Cap Rs m168,625378,170 44.6%   
No. of employees `00012.012.4 96.8%   
Total wages/salary Rs m20,56121,241 96.8%   
Avg. sales/employee Rs Th8,196.010,585.0 77.4%   
Avg. wages/employee Rs Th1,708.11,707.8 100.0%   
Avg. net profit/employee Rs Th768.51,526.5 50.3%   
INCOME DATA
Net Sales Rs m98,655131,656 74.9%  
Other income Rs m2,0812,011 103.5%   
Total revenues Rs m100,736133,667 75.4%   
Gross profit Rs m15,85829,731 53.3%  
Depreciation Rs m3,2595,986 54.4%   
Interest Rs m3,3461,935 172.9%   
Profit before tax Rs m11,33523,821 47.6%   
Minority Interest Rs m0469 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1,6720-   
Tax Rs m3,7565,303 70.8%   
Profit after tax Rs m9,25018,987 48.7%  
Gross profit margin %16.122.6 71.2%  
Effective tax rate %33.122.3 148.9%   
Net profit margin %9.414.4 65.0%  
BALANCE SHEET DATA
Current assets Rs m66,96884,981 78.8%   
Current liabilities Rs m40,21173,425 54.8%   
Net working cap to sales %27.18.8 309.0%  
Current ratio x1.71.2 143.9%  
Inventory Days Days8375 111.8%  
Debtors Days Days81110 74.1%  
Net fixed assets Rs m33,322133,493 25.0%   
Share capital Rs m2821,024 27.6%   
"Free" reserves Rs m55,770102,839 54.2%   
Net worth Rs m56,052103,863 54.0%   
Long term debt Rs m35,73839,497 90.5%   
Total assets Rs m132,888234,831 56.6%  
Interest coverage x4.413.3 33.0%   
Debt to equity ratio x0.60.4 167.7%  
Sales to assets ratio x0.70.6 132.4%   
Return on assets %9.58.9 106.4%  
Return on equity %16.518.3 90.3%  
Return on capital %17.818.3 97.4%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m62,99848,404 130.2%   
Fx outflow Rs m22,85911,593 197.2%   
Net fx Rs m40,14036,811 109.0%   
CASH FLOW
From Operations Rs m13,24228,823 45.9%  
From Investments Rs m-6,990-57,387 12.2%  
From Financial Activity Rs m-7,38718,846 -39.2%  
Net Cashflow Rs m-2,971-7,105 41.8%  

Share Holding

Indian Promoters % 48.3 74.8 64.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 6.9 8.3 83.1%  
FIIs % 34.4 5.9 583.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 11.0 95.5%  
Shareholders   56,727 44,069 128.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   JUBILANT LIFE SCIENCES  DR. DATSONS LABS  WOCKHARDT  GSK PHARMA  PANACEA BIOTECH  

Compare GLENMARK PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 229 Points Lower; Banking and Metal Stocks Witness Selling(Closing)

Indian share markets fell sharply during closing hours today amid weak global cues and disappointing domestic factory output data.

Related Views on News

GLENMARK PHARMA Plunges by 5%; BSE HEALTHCARE Index Down 1.3% (Market Updates)

Nov 13, 2019 | Updated on Nov 13, 2019

GLENMARK PHARMA share price has plunged by 5% and its current market price is Rs 291. The BSE HEALTHCARE is down by 1.3%. The top gainers in the BSE HEALTHCARE Index are ALKEM LABORATORIES (up 5.1%) and NARAYANA HRUDAYALAYA LTD (up 4.8%). The top losers is GLENMARK PHARMA (down 5.4%).

GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 53.1% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, GLENMARK PHARMA has posted a net profit of Rs 1 bn (down 53.1% YoY). Sales on the other hand came in at Rs 23 bn (up 7.3% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (1QFY20); Net Profit Down 28.9% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CADILA HEALTHCARE has posted a net profit of Rs 3 bn (down 28.9% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 6.6% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 6.6% YoY). Sales on the other hand came in at Rs 26 bn (up 12.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

More Views on News

Most Popular

Is Hawkins Set to Become Our Next Superhero Stock?(The 5 Minute Wrapup)

Nov 1, 2019

After PI Industries, Hawkins has put up a stellar show so far.

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

These 10 Days Are Crucial for Getting Rich in the Smallcap Rebound(Profit Hunter)

Nov 5, 2019

How to avoid the most common investing mistake and make the most of the smallcap rebound.

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

What to Buy at Sensex 40,000(The 5 Minute Wrapup)

Nov 4, 2019

Should you invest in high-quality, safe stocks or make some contrarian bets in the smallcap space?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Nov 13, 2019 03:37 PM

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 5-YR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS